Clinical Trials Logo

Filter by:
NCT ID: NCT00040599 Completed - Colorectal Cancer Clinical Trials

Safety Study of 90Y-hMN14 to Treat Colorectal Cancer

Start date: January 2000
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this trial is to determine the safety of 90Y-hMN14 at different dose levels in the treatment of colorectal cancer.

NCT ID: NCT00039000 Completed - Malignant Melanoma Clinical Trials

Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma

Start date: March 2002
Phase: Phase 3
Study type: Interventional

The primary goal of this study is to determine if people with metastatic melanoma who receive Heat Shock Protein-Peptide Complex - 96 (HSPPC-96 or Oncophage) after surgery live longer than people who may or may not have surgery but who receive conventional chemotherapy including IL-2/DTIC. A second goal is to determine the safety and frequency of side effects in subjects who receive therapy with HSPPC-96.

NCT ID: NCT00038467 Completed - Breast Neoplasms Clinical Trials

Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer

IES
Start date: February 1998
Phase: Phase 3
Study type: Interventional

To compare the sequential administration of exemestane with administration of further tamoxifen until 5 years in postmenopausal women with operable breast cancer who have already received 2-3 years of adjuvant tamoxifen, in terms of disease-free survival (DFS), overall survival (OS), incidence of contralateral breast cancer and long-term tolerability.

NCT ID: NCT00036647 Completed - Clinical trials for Carcinoma, Non-small-cell Lung

OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Start date: November 1, 2001
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if OSI-774 will improve overall survival of patients with incurable stage IIIB/IV non-small cell lung cancer compared to standard of care. OSI-774 is a new type of drug under evaluation called an epidermal growth factor receptor (EGFR). OSI-774 is an investigational drug that has not yet been approved by the U.S. Food and Drug Administration (FDA).

NCT ID: NCT00036556 Completed - Prostatic Neoplasms Clinical Trials

Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer

Start date: June 2001
Phase: Phase 3
Study type: Interventional

This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.

NCT ID: NCT00036543 Completed - Prostate Cancer Clinical Trials

A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer

Start date: May 2001
Phase: Phase 3
Study type: Interventional

This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer.

NCT ID: NCT00036179 Completed - Candidiasis Clinical Trials

Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis

Start date: February 27, 1999
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the safety and efficacy of FK463 in the treatment of patients with confirmed candidemia or invasive candidiasis.

NCT ID: NCT00036166 Completed - Aspergillosis Clinical Trials

Study of FK463 for the Treatment of Invasive Aspergillosis

Start date: January 29, 1999
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the safety and efficacy of FK463 in patients with proven or probable invasive infections due to Aspergillus species.

NCT ID: NCT00035308 Completed - Clinical trials for Systemic Lupus Erythematosus

Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether LJP 394 (abetimus sodium) is safe and effective in delaying and reducing renal flares in patients with lupus nephritis.

NCT ID: NCT00035035 Completed - Clinical trials for Pancreatic Neoplasms

A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

Start date: n/a
Phase: Phase 3
Study type: Interventional

Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas. Patients may be able to participate in this study if they have cancer in their pancreas that cannot be removed by surgery OR that has spread to a new site in their body.